Login to Your Account

SGX, Novartis Sign $515M Deal For CML Compounds

By Karen Pihl-Carey

Wednesday, March 29, 2006
Continuing its trend started last year, Novartis AG is offering another $500-million-plus total package for biotech innovation, this time licensing development and commercialization rights to BCR-ABL inhibitors from SGX Pharmaceuticals Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription